Last reviewed · How we verify

Meloxicam and Glucosamine — Competitive Intelligence Brief

Meloxicam and Glucosamine (Meloxicam and Glucosamine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + nutraceutical combination. Area: Rheumatology / Orthopedics.

phase 3 NSAID + nutraceutical combination COX-2 (meloxicam); cartilage matrix precursor (glucosamine) Rheumatology / Orthopedics Small molecule Live · refreshed every 30 min

Target snapshot

Meloxicam and Glucosamine (Meloxicam and Glucosamine) — Zodiac Produtos Farmaceuticos S.A.. Meloxicam reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while glucosamine supports cartilage structure and may reduce joint degradation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Meloxicam and Glucosamine TARGET Meloxicam and Glucosamine Zodiac Produtos Farmaceuticos S.A. phase 3 NSAID + nutraceutical combination COX-2 (meloxicam); cartilage matrix precursor (glucosamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + nutraceutical combination class)

  1. Zodiac Produtos Farmaceuticos S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Meloxicam and Glucosamine — Competitive Intelligence Brief. https://druglandscape.com/ci/meloxicam-and-glucosamine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: